tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
AIDS-Associated Nephropathy D016263 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Vestibular Diseases D015837 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
HIV Infections D015658 20 associated lipids
Histiocytosis D015614 2 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Reperfusion Injury D015427 65 associated lipids
Scleritis D015423 3 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Discitis D015299 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Dementia, Vascular D015140 7 associated lipids
Wounds, Stab D014951 3 associated lipids
West Nile Fever D014901 1 associated lipids
Vomiting D014839 21 associated lipids
Vitiligo D014820 2 associated lipids
Vision Disorders D014786 10 associated lipids
Viremia D014766 4 associated lipids
Venous Insufficiency D014689 2 associated lipids
Vasculitis D014657 14 associated lipids
Vascular Diseases D014652 16 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Dumont FJ et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. 1990 J. Immunol. pmid:1688572
Cadoff EM et al. Assay of FK 506 in plasma. 1990 Transplant. Proc. pmid:1689898
Venkataramanan R et al. Pharmacokinetics of FK 506: preclinical and clinical studies. 1990 Transplant. Proc. pmid:1689899
Jain AB et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. 1990 Transplant. Proc. pmid:1689900
Fung JJ et al. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. 1990 Transplant. Proc. pmid:1689901
Zeevi A et al. Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. 1990 Transplant. Proc. pmid:1689902
Imventarza O et al. Renal transplantation in baboons under FK 506. 1990 Transplant. Proc. pmid:1689903
Monden M et al. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. 1990 Transplant. Proc. pmid:1689904
Ericzon BG et al. Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey. 1990 Transplant. Proc. pmid:1689905
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Tze WJ et al. In vitro effects of FK-506 on human and rat islets. 1990 Transplantation pmid:1694319
Maki N et al. Complementary DNA encoding the human T-cell FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from cyclophilin. 1990 Proc. Natl. Acad. Sci. U.S.A. pmid:1695378
Doe SE et al. Early effects of the immunosuppressive drug FK-506 on signal transduction in lymphocytes. 1990 Biochem. Soc. Trans. pmid:1695581
Murase N et al. Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. 1990 Transplantation pmid:1696405
Propper DJ et al. FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. 1990 Transplantation pmid:1696409
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Standaert RF et al. Molecular cloning and overexpression of the human FK506-binding protein FKBP. 1990 Nature pmid:1696686
Tropschug M et al. Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. 1990 Nature pmid:1696687
Randall T New antirejection drugs anticipated. 1990 JAMA pmid:1696999
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Isai H et al. FK 506 and orthotopic liver transplantation in the rat. 1990 Transplant. Proc. pmid:1699329
Suzuki S et al. In vivo 31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK506. 1990 Heart Vessels pmid:1699922
Bierer BE et al. Probing immunosuppressant action with a nonnatural immunophilin ligand. 1990 Science pmid:1700475
Murase N et al. FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. 1990 Transplantation pmid:1700504
Burke MD et al. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. 1990 Transplantation pmid:1700507
Fung JJ et al. Overview of FK506 in transplantation. 1990 Clin Transpl pmid:1715740
Pugh-Humphreys RG et al. The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. 1990 Immunology pmid:1696242
Mochizuki M and Kawashima H Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. 1990 Autoimmunity pmid:1717007
Ni M et al. FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. 1990 Autoimmunity pmid:1717008
Collier SJ Immunosuppressive drugs. 1989-1990 Curr. Opin. Immunol. pmid:2484794
McCauley J et al. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. 1989 Dec 23-30 Lancet pmid:2481200
Inagaki K et al. Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation. 1989 Transplant. Proc. pmid:2468210
Gudas VM et al. Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. 1989 Transplant. Proc. pmid:2468211
Sato K et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. 1989 Transplant. Proc. pmid:2468212
Watanabe K et al. Prolongation effect of a small dose of FK506, cyclosporine, or azathioprine on renal allografts in dogs treated with fractionated lymphoid irradiation and donor bone marrow cell infusion. 1989 Transplant. Proc. pmid:2468213
Sakamoto K et al. Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506. 1989 Transplant. Proc. pmid:2468222
Nakajima K et al. Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. 1989 Transplant. Proc. pmid:2468223
Ochiai T et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. 1989 Transplant. Proc. pmid:2468228
Yasunami Y et al. Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat. 1989 Transplant. Proc. pmid:2468234
Kay JE et al. The mechanism of action of the immunosuppressive drug FK-506. 1989 Cell. Immunol. pmid:2478301
Starzl TE et al. FK 506 for liver, kidney, and pancreas transplantation. 1989 Lancet pmid:2478846
Arai K et al. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. 1989 Transplantation pmid:2479130
Francavilla A et al. Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. 1989 Lancet pmid:2479802
Walliser P et al. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. 1989 Immunology pmid:2480331
Aoki M et al. [Histological observations of immunosuppressive effects of FK-506 in canine lung allotransplantation]. 1989 Bull Chest Dis Res Inst Kyoto Univ pmid:2482787
Kay JE and Benzie CR T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506. 1989 Immunol. Lett. pmid:2483716